about
Restoration of frontal activation during a treatment with quetiapine: an fMRI study of blunted affect in schizophreniaIncreased grey matter densities in schizophrenia patients with negative symptoms after treatment with quetiapine: a voxel-based morphometry study.Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine.Subjective and Objective Cognitive Dysfunction in Schizophrenia - is there a Link?Cerebral activity associated with auditory verbal hallucinations: a functional magnetic resonance imaging case studyClozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses.Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis.On the trail of a cognitive enhancer for the treatment of schizophrenia.Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment.The paradox of quetiapine in obsessive-compulsive disorder.Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder.The crossover approach to switching antipsychotics: what is the evidence?Progesterone and Cerebral Function during Emotion Processing in Men and Women with Schizophrenia.Relationships between Brain Structure and Metabolic Changes in Schizophrenia Patients Treated with Olanzapine: A Voxel-Based Morphometric Study.Plasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the "Mirror Effect" of SchizophreniaA meta-analysis of negative symptoms in dual diagnosis schizophrenia.Fatal agranulocytosis: the use of olanzapine in a patient with schizophrenia and myelodysplasia.Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB.Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis.Markedly Reduced Thermal Pain Perception in a Schizoaffective Patient with Tardive DyskinesiaOral cholinesterase inhibitor add-on therapy for cognitive enhancement in schizophrenia: a quantitative systematic review, Part I.Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: a systematic quantitative review, part 2.Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review.The neural correlates of mental rotation abilities in cannabis-abusing patients with schizophrenia: an FMRI study.A randomized controlled trial with a Canadian electronic pill dispenser used to measure and improve medication adherence in patients with schizophrenia.Altered brain connectivity in patients with schizophrenia is consistent across cognitive contextsAntipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis.Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials.Sexual dimorphism in schizophrenia: is there a need for gender-based protocols?Ziprasidone for psychotic disorders: a meta-analysis and systematic review of the relationship between pharmacokinetics, pharmacodynamics, and clinical profile.Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.Discriminant cognitive factors in responder and non-responder patients with schizophrenia.A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder.Multisite generalizability of schizophrenia diagnosis classification based on functional brain connectivity.Switching atypical antipsychotics: a review.A neuroimaging study of emotion-cognition interaction in schizophrenia: the effect of ziprasidone treatment.[Schizophrenia and addiction: An evaluation of the self-medication hypothesis]Clozapine and visuospatial processing in treatment-resistant schizophrenia.Predictors of community functioning in schizophrenia and substance use disorder patients.
P50
Q28299247-11FD4F35-ADBE-4152-9268-ADD1733BF514Q34601850-FB8FD3C0-9447-4120-A97E-647DF300F681Q34994773-6CFD333A-5A1C-4BEC-8BAA-7C69E76DA8FAQ35091697-31A859AF-A928-498F-8F58-6EB79D1659D5Q35100095-43CB807D-CE41-4E71-A24A-4AE405AD2BC1Q35110251-3E4ECD3C-0B4F-4962-B669-5765CCCAF65CQ35566086-78D99867-28CA-4A9A-89C8-5AE193D6FC0FQ36031978-362A28EE-B659-4334-8913-FCE2DDCA1D97Q36061639-52E495EF-44D8-4B78-8820-4D4F7FB19B35Q36109593-608DC1E9-7676-4533-A97B-DE40339C481CQ36142165-51010C47-3517-40FE-AC3C-03150897F5D1Q36159323-C9CC028D-4520-4C70-AB50-BEAC426B46A3Q36169081-3101B393-D123-44C0-BAEC-B9F74AD523DAQ36169521-6FE77F4F-6A8B-4143-A67A-16999BF4FB88Q36275995-FC044C1C-52A1-49A1-814E-6A6C013A22BEQ36421120-4AF24111-A410-411E-8B65-40CCFD77AAAFQ36595340-BF41587A-92D2-40AC-B157-733946B94D8FQ36709736-7AFEAB49-8283-4B13-B05C-5CB5048F7AD3Q36809061-FF370FF1-A56C-4CF7-9D25-844FC2B33B89Q36828254-C6230F0E-4860-456A-B3AC-E98670AD37B7Q36838872-B761ECD0-69A6-461B-AB94-09F8AE428689Q36924985-8A61E020-A025-45B5-952F-15A7E015B282Q37001984-FB31D6F9-AE0E-494D-8B4A-997F3AB133D2Q37061404-898B5C93-41EA-41B5-A9C5-2EFDFEED0540Q37083505-CC003952-DF35-4EE6-820C-FFA17BDE716DQ37730420-CA53BA0C-B07C-4956-BD4B-B6919EF46A40Q37772743-09EAA8E6-860B-44D1-9F41-2C9D05E5F8BAQ37849555-96B267D6-BF78-4348-BAE9-755AFF058A40Q37896624-0DAA0F56-B934-4127-AD30-BEF5985230C0Q37963622-0BE73BF2-074E-46BE-AB83-52A697A363B3Q38042430-A2265EF0-5203-47EC-A9DB-CF5EB08B9E17Q38042478-73E3C372-45FF-4161-A108-CBE3BA17FEBFQ38446439-212ABC58-0EEF-4BE0-A343-ED341539E9E0Q38488339-76140B94-67B2-4559-B2F2-8175F4A3FDE2Q38732368-00114D71-B148-459B-B4A8-4F1AB7042B87Q38777655-3B119A3B-1DCA-470C-8A4F-C7900A7DEEBBQ38955981-26002417-CEB2-4A63-8FFC-8022A72C5E90Q39392325-ED90874F-6F6D-4B81-AFDE-18BC0BF959C9Q39480375-1DC6FDA5-0AF0-495C-8D66-F15BC0F2B759Q39577163-84026E12-1AA0-488D-AA6E-B22F5F218685
P50
description
Canadees psychiater
@nl
kanadischer Psychiater
@de
psichiatra canadese
@it
psikiatra kanadarra
@eu
psiquiatra canadense
@gl
psiquiatra canadiano
@pt
psiquiatra canadianu
@ast
psiquiatra canadiense
@es
psiquiatre canadenc
@ca
psychiatre canadien
@fr
name
Emmanuel Stip
@ast
Emmanuel Stip
@ca
Emmanuel Stip
@en
Emmanuel Stip
@es
Emmanuel Stip
@fr
Emmanuel Stip
@ga
Emmanuel Stip
@nl
Emmanuel Stip
@sl
Emmanuel Stip
@sq
type
label
Emmanuel Stip
@ast
Emmanuel Stip
@ca
Emmanuel Stip
@en
Emmanuel Stip
@es
Emmanuel Stip
@fr
Emmanuel Stip
@ga
Emmanuel Stip
@nl
Emmanuel Stip
@sl
Emmanuel Stip
@sq
prefLabel
Emmanuel Stip
@ast
Emmanuel Stip
@ca
Emmanuel Stip
@en
Emmanuel Stip
@es
Emmanuel Stip
@fr
Emmanuel Stip
@ga
Emmanuel Stip
@nl
Emmanuel Stip
@sl
Emmanuel Stip
@sq
P269
P101
P106
P2038
Emmanuel_Stip
P21
P214
P269
P27
P31
P496
0000-0003-2859-2100
P735
P7859
viaf-104851867
viaf-282853158